HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Wholesalers Face Pressing Need to Retool Biz Strategy as Generics Gain Ground

Lexicon

Pricing premium for the promotion of new drug development and the elimination/resolution of off-label use:
新薬創出・適応外薬解消等促進加算(新薬創出加算)

The Column

What’s Your Pharma Company’s Brand in Japan?

Archives

Lupus Nephritis to Be Added to Cellcept’s Indication: MHLW Notification(Aug.04)
Daiichi Sankyo to Submit 4 Products for Approval in Japan and Overseas through FY2018(Aug.04)
Edoxaban Doing Well in Japan, but Off to a Rocky Start in US: Daiichi Sankyo(Aug.04)
Astellas Not Keen on Biosimilars: CFO Masuda(Aug.04)
Japan’s 1st Insulin Biosimilar Launched: Eli Lilly Japan, NBI(Aug.04)

News Calendar